Ignite Creation Date:
2025-12-24 @ 7:19 PM
Ignite Modification Date:
2025-12-30 @ 7:45 PM
Study NCT ID:
NCT00720603
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2015-03-24
First Post:
2008-07-21
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.
Sponsor:
Genzyme, a Sanofi Company
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
MOZ00607
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None